These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Prospective Evaluation of Song H; Harrison C; Duan H; Guja K; Hatami N; Franc BL; Moradi F; Aparici CM; Davidzon GA; Iagaru A J Nucl Med; 2020 Apr; 61(4):546-551. PubMed ID: 31628216 [No Abstract] [Full Text] [Related]
46. Imaging of Prostate Cancer Using Castellucci P; Ceci F; Fanti S PET Clin; 2017 Apr; 12(2):137-143. PubMed ID: 28267448 [TBL] [Abstract][Full Text] [Related]
47. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Bauman G; Belhocine T; Kovacs M; Ward A; Beheshti M; Rachinsky I Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):45-55. PubMed ID: 21844889 [TBL] [Abstract][Full Text] [Related]
48. The efficacy of transrectal ultrasound and prostate cancer. Mandell MJ; Hopper KD; Jarowenko MV; Rohner TJ; Belis JA; Stryker JA; Meilstrup JW; Thieme GA Crit Rev Diagn Imaging; 1991; 32(4):273-300. PubMed ID: 1958294 [TBL] [Abstract][Full Text] [Related]
49. Molecular Imaging and Theranostics-A Multidisciplinary Approach. Farolfi A; Lima GM; Oyen W; Fanti S Semin Nucl Med; 2019 Jul; 49(4):247-254. PubMed ID: 31227048 [TBL] [Abstract][Full Text] [Related]
50. The expanding landscape of diffusion-weighted MRI in prostate cancer. Wibmer AG; Sala E; Hricak H; Vargas HA Abdom Radiol (NY); 2016 May; 41(5):854-61. PubMed ID: 26814501 [TBL] [Abstract][Full Text] [Related]
51. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer. Hennenfent BR Br J Urol; 1998 Jul; 82(1):166. PubMed ID: 9698691 [No Abstract] [Full Text] [Related]
52. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. Schilling D; Schlemmer HP; Wagner PH; Böttcher P; Merseburger AS; Aschoff P; Bares R; Pfannenberg C; Ganswindt U; Corvin S; Stenzl A BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442 [TBL] [Abstract][Full Text] [Related]
53. Dynamic contrast-enhanced imaging in localizing local recurrence of prostate cancer after radiotherapy: Limited added value for readers of varying level of experience. Luzurier A; Jouve De Guibert PH; Allera A; Feldman SF; Conort P; Simon JM; Mozer P; Compérat E; Boudghene F; Servois V; Lucidarme O; Granger B; Renard-Penna R J Magn Reson Imaging; 2018 Oct; 48(4):1012-1023. PubMed ID: 29517822 [TBL] [Abstract][Full Text] [Related]
54. Role of PET-CT with Puche-Sanz I; Triviño-Ibáñez E; Vázquez-Alonso F; Llamas-Elvira JM; Cózar-Olmo JM; Rodríguez-Fernández A Actas Urol Esp; 2017 Sep; 41(7):437-444. PubMed ID: 28389027 [TBL] [Abstract][Full Text] [Related]
55. [Efficacy of transrectal ultrasonography in staging prostate cancer]. Soh S; Egawa S Nihon Rinsho; 1998 Aug; 56(8):2036-41. PubMed ID: 9750503 [TBL] [Abstract][Full Text] [Related]
56. Prostate-Specific Membrane Antigen PET/Magnetic Resonance Imaging for the Planning of Salvage Radiotherapy in Patients with Prostate Cancer with Biochemical Recurrence After Radical Prostatectomy. Elschot M; Selnæs KM; Langørgen S; Johansen H; Bertilsson H; Tandstad T; Bathen TF PET Clin; 2019 Oct; 14(4):487-498. PubMed ID: 31472746 [TBL] [Abstract][Full Text] [Related]
57. ['Men are not dying with, but from prostate cancer']. Stief C MMW Fortschr Med; 2014 Dec; 156(21-22):66. PubMed ID: 25608413 [No Abstract] [Full Text] [Related]
58. Overuse of imaging for staging low risk prostate cancer. Choi WW; Williams SB; Gu X; Lipsitz SR; Nguyen PL; Hu JC J Urol; 2011 May; 185(5):1645-9. PubMed ID: 21419444 [TBL] [Abstract][Full Text] [Related]
59. Prostate cancer diagnosis and management. Frydenberg M; Stricker PD; Kaye KW Lancet; 1997 Jun; 349(9066):1681-7. PubMed ID: 9186395 [No Abstract] [Full Text] [Related]